A high immunohistochemical (IHC) staining of PD-L1 tumor expression [37,38] and/or PD-1 and CTLA-4 TILs expression [39] on biopsy specimens is the first fundamental step for treatment selection, being generally but not only related to higher response rate to ICI therapy. Here, CD274 is linked to neoplasm.